Related references
Note: Only part of the references are listed.EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling
Chun-Ju Chang et al.
CANCER CELL (2011)
Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer
Maria E. Gonzalez et al.
CANCER RESEARCH (2011)
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1
M. E. Gonzalez et al.
ONCOGENE (2009)
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
Julian Puppe et al.
BREAST CANCER RESEARCH (2009)
Improving decision-making in early breast cancer: who to treat and how?
Antonio Llombart-Cussac
BREAST CANCER RESEARCH AND TREATMENT (2008)
Current issues in ER and HER2 testing by IHC in breast cancer
Allen M. Gown
MODERN PATHOLOGY (2008)
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
Q. Cao et al.
ONCOGENE (2008)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast
Lei Ding et al.
CANCER RESEARCH (2006)
Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer
Yasuko Matsukawa et al.
CANCER SCIENCE (2006)
Polycomb complexes repress developmental regulators in murine embryonic stem cells
LA Boyer et al.
NATURE (2006)
Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues
L Ding et al.
CANCER RESEARCH (2006)
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer
K Collett et al.
CLINICAL CANCER RESEARCH (2006)
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
IM Bachmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder
JD Raman et al.
CLINICAL CANCER RESEARCH (2005)
The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells
M Zeidler et al.
NEOPLASIA (2005)
Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
T Sudo et al.
BRITISH JOURNAL OF CANCER (2005)
Increased expression of EZH2, a polycomb group protein, in bladder carcinoma
S Arisan et al.
UROLOGIA INTERNATIONALIS (2005)
MLL: a histone methyltransferase disrupted in leukemia
JL Hess
TRENDS IN MOLECULAR MEDICINE (2004)
Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis
RHJ Breuer et al.
NEOPLASIA (2004)
Epigenetic regulation of cellular memory by the polycomb and trithorax group proteins
L Ringrose et al.
ANNUAL REVIEW OF GENETICS (2004)
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
AP Bracken et al.
EMBO JOURNAL (2003)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene
FM Raaphorst et al.
NEOPLASIA (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans
SS Levine et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Share Paper
